News and Trends 28 Jul 2022 First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association Sandoz, a global pharmaceutical company working in generic and biosimilar medicines, announced this week that the US Food and Drug Administration (FDA) has accepted its biologics application (BLA) for treatment for people with multiple sclerosis (MS). The application is for a biosimilar natalizumab developed by Polpharma Biologics and includes all indications covered by the reference […] July 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Commercial launch of Monkeypox PCR test announced for research A PCR test to pick up the monkeypox virus is now available outside the US for use in research applications by laboratories. Becton, Dickinson and Company (BD) a global medical technology company and CerTesy Biotec made the announcement today (July 27). The BD MAX System used to leverage the test is a fully integrated, automated […] July 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 AbbVie seeks nod from FDA and EMA for Crohn’s disease drug U.S. biopharma company AbbVie has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ) for the treatment of adult patients with moderately to severely active Crohn’s disease. “Crohn’s disease can be debilitating and have a significant impact on a person’s daily life,” […] July 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 T-cell therapy company AlloVir set to raise $126.6M AlloVir, Inc., a late clinical-stage allogeneic T-cell immunotherapy company, has entered into a securities purchase agreement with a group of institutional and strategic investors to sell 27,458,095 shares of common stock in a registered direct offering at a purchase price of $4.61 per share. Gross proceeds from the offering will equal approximately $126.6 million. The […] July 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 Diffusion Pharmaceuticals to start brain tumor clinical trial U.S. biopharma company Diffusion Pharmaceuticals Inc. is set to start a new phase 2 clinical trial. Entitled “Open-Label, Dose-Escalation, Phase 2 Safety and Efficacy Study of TSC in Newly Diagnosed Glioblastoma (GBM) Patients when Administered with Standard of Care (“SOC”),” the company said the trial is a result of a collaboration with the United States […] July 27, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 SOTIO Biotech starts solid tumor trial SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group is starting its phase 2 trial on patients with selected advanced/refractory solid tumors. The company has dosed its first patient in the AURELIO-04 combination trial of SOT101 and MSD’s (Merck & Co., Inc., Rahway, NJ) anti-PD-1 therapy KEYTRUDA (pembrolizumab). “The initiation of this phase […] July 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 Oryzon collaborating with CMT Research Foundation in the US Spanish biopharma company Oryzon Genomics, S.A. is starting a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, to explore Oryzon’s histone deacetylase 6 (HDAC6) inhibitors. HDAC6 inhibitors have been previously described as potentially effective treatments for CMT. Oryzon has recently […] July 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 SomaLogic acquires DNA nanotechnology company Palamedrix Colorado-based AI data-driven proteomics technology company SomaLogic has entered into an agreement to acquire Palamedrix, Inc., which is involved in DNA nanotechnology. Palamedrix provides scientific and engineering expertise and miniaturization technology, which SomaLogic intends to leverage as it develops the next generation of the SomaScan assay. Proteomic tool The SomaScan assay is a multiplexed, sensitive, quantitative, […] July 27, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 27 Jul 2022 The race to uncloak cancer with liquid biopsies Until recently, cancer detection depended on invasive solid tissue sampling that didn’t provide a complete picture. An emerging crowd of biotechs is making it easier to detect and monitor cancer with liquid biopsies. The notion that a person’s blood can reveal a wealth of health information looked so shiny that the infamous blood diagnostics company […] July 27, 2022 - 10 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Pleco Therapeutics expands into U.S. and names president Pleco Therapeutics BV, a biopharmaceutical company based in the Netherlands, has expanded, with the incorporation of a U.S. subsidiary, Pleco Therapeutics USA. Pleco Therapeutics, which develops novel treatments designed to detoxify the cancer promoting cellular micro-environment, also named Michael Stalhamer as the US subsidiary’s president and first employee. Stalhamer also serves on the global leadership […] July 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 InflaRx announces plans to apply for Emergency Use Authorization for new COVID-19 drug A biopharmaceutical company developing anti-inflammatory therapeutics announced today (July 26) that it is going to submit a request for Emergency Use Authorization (EUA). InflaRx made the announcement after encouraging interactions with the US Food and Drug Administration (FDA) at a recent meeting. The company had requested the meeting to discuss a potential EUA submission regarding […] July 26, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Irish agritech start-up CropBiome receives €1.3M investment Irish agritech startup CropBiome, a joint University College Dublin (UCD) and Trinity College Dublin (TCD) spin-out, has received €1.3 million ($1.3 million) funding. HBAN (Halo Business Angel Network), the all-island organization responsible for the promotion of business angel investment, and a joint initiative of Enterprise Ireland, InterTradeIreland and Invest Northern Ireland, participated in the oversubscribed […] July 26, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email